FMR LLC and Abigail P. Johnson filed a Schedule 13G with the SEC on November 4, 2026, disclosing beneficial ownership of common stock in Definium Therapeutics Inc. as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: FMR LLC and Abigail P. Johnson each reported beneficial ownership of 8,791,720.34 shares of Definium Therapeutics Inc. common stock (CUSIP 24477V105).
  • Percent of class: The aggregate amount represents 6.5% of the outstanding common stock, according to the filing.
  • Sole voting power (FMR LLC): FMR LLC reported sole voting power over 8,733,063.58 shares, with no shared voting power.
  • Sole dispositive power: Both FMR LLC and Abigail P. Johnson each reported sole dispositive power over 8,791,720.34 shares, with no shared dispositive power.
  • Triggering event date: The date of the event requiring this filing was September 30, 2026.
  • Ordinary course certification: The filing certifies the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

FMR LLC and Abigail P. Johnson Disclose Ownership Position in Definium Therapeutics

According to the Schedule 13G filed November 4, 2026, FMR LLC, a Delaware-organized holding company located at 245 Summer Street, Boston, Massachusetts 02210, reported aggregate beneficial ownership of 8,791,720.34 shares of common stock in Definium Therapeutics Inc., whose principal executive offices are listed at One World Trade Center, Suite 8500, New York, NY 10007. The filing identifies FMR LLC as a parent holding company or control person (type "HC") under the applicable SEC classification.

Abigail P. Johnson, a United States citizen classified as an individual (type "IN"), is also named as a reporting person. She reported the same aggregate beneficial ownership figure of 8,791,720.34 shares, representing 6.5% of the class, with sole dispositive power over all such shares and no voting power of her own. FMR LLC, by contrast, reported sole voting power over 8,733,063.58 shares. The filing notes that one or more other persons are known to have the right to receive or direct receipt of dividends or sale proceeds from the common stock, but states that no single other person holds an interest exceeding 5% of the total outstanding common stock.

The filing was signed by Stephanie J. Brown on behalf of both FMR LLC and Abigail P. Johnson under duly authorized powers of attorney dated January 3, 2023, and January 26, 2023, respectively. The filing references Exhibit 99 for identification and classification of the relevant subsidiaries through which the position is held, as required when a parent holding company files the schedule.

What Was Disclosed

FMR LLC and Abigail P. Johnson disclosed through a Schedule 13G a combined 6.5% beneficial ownership stake, equaling 8,791,720.34 shares, of Definium Therapeutics Inc. common stock, with the triggering event dated September 30, 2026.